TOFATAS TAB

About

Tofacitinib is an oral Janus kinase (JAK) inhibitor, a targeted synthetic disease-modifying antirheumatic drug (tsDMARD), used in the treatment of various autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Its mechanism of action involves inhibiting the activity of specific JAK enzymes, particularly JAK1 and JAK3, which are crucial components of intracellular signaling pathways for numerous cytokines and growth factors. By blocking these pathways, tofacitinib disrupts the signaling cascade initiated by inflammatory cytokines like interleukins and interferons, thereby modulating immune responses and reducing inflammation. This targeted approach helps to alleviate symptoms, reduce disease activity, and potentially slow disease progression in patients who have had an inadequate response or intolerance to other therapies. Close monitoring for infections and other adverse events is essential during treatment.

Uses

• Treatment of rheumatoid arthritis.
• Management of psoriatic arthritis.
• Treatment of ulcerative colitis.
• Management of ankylosing spondylitis.

Directions For Use

Take orally, usually once or twice daily, with or without food.

Benefits

• Effective for various autoimmune conditions.
• Reduces inflammation and disease activity.
• Oral administration offers convenience.
• Targets specific cytokine signaling pathways.
• Can improve physical function.
• May reduce joint damage progression.

Side Effects

• Upper respiratory tract infections
• Headache
• Diarrhea
• Nausea
• Nasopharyngitis
• Increased risk of serious infections (e.g., herpes zoster)
• Lymphopenia
• Anemia
• Elevated cholesterol levels
• Increased risk of thrombosis (DVT, PE)
• Liver enzyme elevations
• Gastrointestinal perforation (rare)

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but excessive alcohol may increase the risk of liver issues.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm; use only if clearly needed and benefits outweigh risks.
• Breastfeeding - Tofacitinib is excreted in breast milk; breastfeeding is not recommended due to potential adverse effects on the infant.
• Liver - Use with caution in patients with moderate to severe hepatic impairment; dose adjustment may be necessary.
• Kidney - Dose adjustment is required for patients with moderate to severe renal impairment.
• Lung - Use with caution in patients with pre-existing lung conditions, as it may increase the risk of serious infections, including opportunistic infections.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.